StockData

Intercure Ltd. (INCR) stock

INCRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 30, 2026Score 3/30
$3.63−0.16 (-4.22%)

Close on Nov 16, 2026Market cap $198.49MP/E –Yield –

Intercure r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was 390.00K ILS, down 5.8% from the year before. The highest annual figure on record is 1.71M ILS in fiscal 2019.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025390.00K ILS-5.8%
FY2024Dec 31, 2024414.00K ILS+6.7%
FY2023Dec 31, 2023388.00K ILS-38.6%
FY2022Dec 31, 2022632.00K ILS-48.8%
FY2021Dec 31, 20211.24M ILS-21.6%
FY2020Dec 31, 20201.58M ILS-7.8%
FY2019Dec 31, 20191.71M ILS–

More Intercure figures

See a number that looks wrong?